Kura Oncology reports positive Phase 2 KOMET-001 trial of ziftomenib in R/R NPM1-m AML

Kura Oncology, Inc.

KOMET-001 achieved primary endpoint CR+CRh with statistical significance; benefit-risk profile encouraging.
NDA submission to FDA for ziftomenib in R/R NPM1-m AML on track for Q2 2025.
Plans to initiate two Phase 3 frontline trials (KOMET-017) in 2H 2025 with dual-primary endpoints for potential accelerated and full approval.
Multiple data presentations expected in 2025 across ziftomenib, KO-2806, and tipifarnib programs.
Collaboration with Kyowa Kirin continues for commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.